教員・教室員について

助教

名前 森 康雄(もり やすお)
卒業年 2001(平成13)年
学位取得年月 2009年 医学博士学位取得
専門領域 血液内科学、造血細胞移植、幹細胞学
資格 日本内科学会認定医・専門医、日本血液学会専門医・指導医・評議員 日本造血細胞移植学会・認定医・評議員
所属学会 日本内科学会、日本血液学会、日本造血細胞移植学会、日本輸血細胞治療学会

略歴

2001~2003年

九州大学病院、九州医療センター、亀田総合病院

2004~2010年

九州大学病態修復内科学、遺伝子細胞療法部

2010~2013年

日本学術振興会 特別研究員

2011~2014年

スタンフォード大学幹細胞生物学・再生医療研究所 研究員

2014年4月

九州大学病院 遺伝子細胞療法部 臨床助教

2015年4月

九州大学病院 血液・腫瘍内科 助教

代表的業績

  1. Mori Y, et al. Distinctive expression of myelomonocytic markers and downregulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation. Eur J Haematol. 2007; 20: 3010-21
  2. Kikushige Y, et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol. 180(11): 7358-67. 2008
  3. Yoshimoto G, et al. FLT3-ITD upregulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 114(24):5034-43. 2009
  4. Mori Y, et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J Exp Med. 206(1):183-93. 2009
  5. Mori Y, et al. High incidence of human herpes virus 6-associated encephalitis/myelitis following a second unrelated cord blood transplantation. Biol Blood Marrow Transplant. 16(11):1596-602. 2010
  6. Mori Y, et al. High incidence of false-positive Aspergillus galactomannan test in multiple myeloma. Am J Hematol. 85(6):449-51. 2010
  7. Mori Y, et al. Different risk factors related to adenovirus- or BK virus-associated hemorrhagic cystitis following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 18(3):458-65. 2012
  8. Kikushige Y, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 20(2):246-59. 2011
  9. Mori Y, et al. Diagnostic value of serum procalcitonin and C-reactive protein for infections after allogeneic hematopoietic stem cell transplantation versus nontransplant setting. Intern Med. 50(19):2149-55. 2011
  10. Mori Y, et al. Validation of pretransplantation assessment of mortality risk score in the outcome of hematopoietic SCT in non-Caucasians. Bone Marrow Transplant. 47(8):1075-81. 2012
  11. Miyanishi M*, Mori Y*, et al. (equally contributed) Do pluripotent stem cells exist in adult mice as very small embryonic stem cells? Stem Cell Reports. 1(2):198-208. 2013
  12. Ho CC et al. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    J Biol Chem. 2015 May 15;290(20):12650-63.
  13. Mori Y et al. Prospective isolation of human erythroid lineage-committed progenitors.
    Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9638-43.
  14. Yoshimoto G, , et al.Human Herpes Virus-6-Associated Encephalitis/Myelitis Mimicking Calcineurin Inhibitor-Induced Pain Syndrome in Allogeneic Stem Cell Transplantation Recipients.
    Biol Blood Marrow Transplant. 2018 Dec;24(12):2540-2548. 
  15. Mori Y, , et al.Gastrointestinal Graft-versus-Host Disease Is a Risk Factor for Postengraftment Bloodstream Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
    Biol Blood Marrow Transplant. 2018 Nov;24(11):2302-2309. 
  16. Mori Y*, et al.Previous exposure to bortezomib is linked to a lower risk of engraftment syndrome after autologous hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2019 Jan;60(1):271-273. 
  17. Zhu F, et al.Screening for genes that regulate the differentiation of human megakaryocytic lineage cells.
    Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9308-E9316. 
  18. Miyawaki K, et al.Identification of unipotent megakaryocyte progenitors in human hematopoiesis.
    Blood. 2017 Jun 22;129(25):3332-3343. 
  19. Mori Y, et al.Ruxolitinib treatment for GvHD in patients with myelofibrosis.
    Bone Marrow Transplant. 2016 Dec;51(12):1584-1587.